

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2026.

Commission File Number: 001-40530

**GH Research PLC**  
(Exact name of registrant as specified in its charter)

Joshua Dawson House  
Dawson Street  
Dublin 2  
D02 RY95  
Ireland  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F \_\_\_\_\_  \_\_\_\_\_ Form 40-F \_\_\_\_\_

---

---

---

## EXHIBIT INDEX

Exhibit No.	Description
<a href="#">99.1</a>	Press release dated January 2, 2026

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 2, 2026

**GH Research PLC**

By: /s/ Julie Ryan  
Name: Julie Ryan  
Title: Vice President, Finance

---

**GH Research to Announce IND Status for GH001**

DUBLIN, January 2, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST.

**About GH Research PLC**

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.

**About GH001**

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 ( $p < 0.0001$ ), we believe that GH001 has the potential to change the way TRD is treated today.

**Investor Relations:**

Julie Ryan  
GH Research PLC  
[investors@ghres.com](mailto:investors@ghres.com)

---